Novonesis B Unsp/Adr

Thank you, operator, and welcome, everyone. Thank you for joining us. My name is Tobias Björklund, and I'm the head of Investor Relations at Novozymes. At this call, Esther Bacher, CEO of Novozymes, and Lars Grain, our CFO, will go through our performance for the first nine months of 2020, the outlook for the full year, and comment on the recent changes to our organizational setup. We expect the presentation to take roughly 20 minutes, after which we will open up for questions. Also with us today, we have the rest of the management team, namely Anders Lund, EVP Consumer BioSolutions, Tina Feiner, EVP Industrial BioSolutions, Thomas Widerbeck, Interim EVP of Strategy and Business Transformation, as well as People, Sustainability and Brand, Claes Fuglsang, Chief Science Officer, and Graciela Maluceli, Chief of Operations. We expect the entire call to take 50 minutes. Before we begin, I would like to remind you that the information presented at the call is unaudited and that management may make forward-looking statements. These statements are based on current expectations and beliefs and involve risks and uncertainties that could cause actual results to differ materially from those described in any forward-looking statements. With this, I will now hand you over to Esther Bache. Esther, please.

Thank you, Tobias, and thank you all for calling in. Please turn to slide number two. Before we dive into our performance, I'd like to take this opportunity to share our thoughts on the organization setup we announced on September the 1st. The new setup has a clear link to our strategy, better business with biology. The strategy provides a solid foundation, and the recent changes allow us to further drive, excuse me, Novozymes ahead more forcefully. It enables us to center ourselves around our customers even more. We have created two divisions following the simple logic of where Novozyne solutions fit in the value chain. In consumer buyer solutions, we gather the segments that have a direct end consumer impact. And in agricultural and industrial buyer solutions, we have group areas with focus on yield and process optimization. With Novozyme's strong foundation and commitment to innovation and production, these two important areas are now represented by dedicated executive vice presidents who report to me. I'll let Klaus and Graciela introduce themselves in a minute. Apart from these new roles, we're also well into the process of hiring two new executive positions currently headed up by Thomas Fiedebach. And now I'll hand over to our CSO, Klaus. And before we hear from our CEO, Graciela. Klaus, please.

Thank you, Esther, and good morning, everyone. My name is Claus Fuglsang. I'm heading up research and development. I've been working with research in enzymes and microbes in my entire professional life and have been part of Nozymes since 1993. I know the potential of biological solutions, and I'm really excited to be part of a world-class R&D organization that helps to unfold this potential every day. I'm committed to ensuring more and a much closer involvement of commercial people and business development in our better translation of consumer needs or customer needs to drive the pipeline for success and growth, while still allowing our passion for world-class science and sustainability to shine through. And now I'll hand over to Graciele. Graciele, please.